Development and Validation of a Novel Prediction Model for Hearing Loss From Cisplatin Chemotherapy

Genitourinary Cancer

Predicting the indication for adjuvant radiation therapy according to EAU guidelines among patients with high-risk prostate cancer: a novel multivariable model

Prostate Cancer Prostatic Dis

Siech C, von Kriegstein H, Wenzel M, Cano Garcia C, Le QC, Tennstedt P, Preisser F, Maurer T, Kriegmair M, Chun FKH, Graefen M, Tilki D, Mandel P

doi: 10.1038/s41391-025-01018-y

Breast Cancer

Predicting ovarian function loss after chemotherapy and anti-HER2 therapy in young breast cancer patients

J Natl Cancer Inst

Lambertini M, Allegranza D, Laubender RP, Harbeck N, Swain SM, Geyer CE, Slamon DJ, Bobba G, Lambertini C, de Haas S, Restuccia E, Vaz-Luis I, Cameron DA, Krop IE, Winer EP, Anderson RA

doi: 10.1093/jnci/djaf198

Genitourinary Cancer

Development and Validation of an Artificial Intelligence Digital Pathology Biomarker to Predict Benefit of Long-Term Hormonal Therapy and Radiotherapy in Men With High-Risk Prostate Cancer Across Multiple Phase III Trials

J Clin Oncol

Armstrong AJ, Liu VYT, Selvaraju RR, Chen E, Simko JP, DeVries S, Sartor O, Sandler HM, Mohamad O, Huang HC, Griffin J, Yamashita R, Esteva A, Tran PT, Spratt DE, Carson JH, Peters C, Gore E, Lee SP, Monson JM, Augspurger ME, El-Gayed A, Rodgers JP, McKay R, Morgan T, Feng FY, Nguyen PL

doi: 10.1200/JCO.24.00365

Genitourinary Cancer

Are NCCN and EAU Active Surveillance Criteria Reliable in Patients With ISUP Grade-2 Intermediate-Risk Prostate Cancer? A Novel Model Integrating MRI to Predict Adverse Pathology

Prostate

Madendere S, Esen B, Karaarslan UC, Müdüroğlu M, Veznikli M, Gürses B, Vural M, Baydar DE, Demirkol MO, Kordan Y, Esen T

doi: 10.1002/pros.70073

Central Nervous System Tumors

Developing an advanced risk stratification model for pediatric intracranial ependymoma based on the prospective trial E-HIT2000 and subsequent registries

Neuro Oncol

von Hoff K, Obrecht-Sturm D, Ghasemi DR, Wenning J, Mynarek M, Gerber NU, Benesch M, Juhnke BO, Bison B, Warmuth-Metz M, Timmermann B, Faldum A, Tippelt S, Fleischhack G, Grotzer M, Driever PH, Beilken A, Ebinger M, Graf N, Frühwald MC, Schmid I, Slavc I, Koch A, Bergmann M, Hagel C, Coras R, Blümcke I, Reifenberger G, Felsberg J, Keyvani K, Harter PN, Prinz M, Staszewski O, Acker T, Stadelmann-Nessler C, Hartmann C, von Deimling A, Sommer C, Hasselblatt M, Riemenschneider MJ, Monoranu CM, Rushing E, Haberler C, Kool M, Sill M, Pfister SM, Schüller U, Pietsch T, Kortmann RD, Kwiecien R, Witt H, Pajtler KW, Rutkowski S, German, Austrian and Swiss HIT-Network

doi: 10.1093/neuonc/noaf218

Genitourinary Cancer

Factors associated with longitudinal progression of the cumulative burden of morbidity and overall mortality after cisplatin-based chemotherapy for testicular cancer

J Natl Cancer Inst

Kerns SL, Dinh PC Jr, Monahan PO, Stump T, Fung C, Sesso HD, Feldman DR, Hamilton RJ, Vaughn DJ, Huddart R, Kollmannsberger C, Martin NE, Nevel K, Kincaid J, Einhorn LH, Travis LB

doi: 10.1093/jnci/djaf014

Lung, Respiratory and Thoracic Cancer

LRP1B loss predicts sensitivity to immunotherapy in patients with NSCLC: an analysis of the phase 3 Checkmate 026 randomized trial

Clin Cancer Res

Armstrong AJ, Dietz H, Balli D, Geese WJ, Duan C, Hung YH, Ip V, Li G, Graf RP, Ready N

doi: 10.1158/1078-0432.CCR-25-0952

Genitourinary Cancer

Olanzapine combined with standard antiemetics for the prevention of nausea and vomiting in patients with germ cell tumor undergoing a 5-day cisplatin-based chemotherapy (NAVIGATE study)： A phase III crossover trial

Eur J Cancer

Zhang L, Chen M, Zhou Q, Xue C, Huang R, Diao X, Li J, Peng J, Zheng Q, Ni M, Zhou L, Wang D, Li H, Yang W, Dun S, Liu Z, Wang Y, Shi Y, An X

doi: 10.1016/j.ejca.2025.115437

Gastrointestinal Cancer

Does the benefit of neoadjuvant chemotherapy at six months predict long-term outcomes in colon or rectal cancer? A meta-analysis of randomised studies

Cancer Treat Rev

Socha J, Michalski W, Glynne-Jones R, Glimelius B, Bujko K

doi: 10.1016/j.ctrv.2025.103020

Related content

Predicting the indication for adjuvant radiation therapy according to EAU guidelines among patients with high-risk prostate cancer: a novel multivariable model

Predicting ovarian function loss after chemotherapy and anti-HER2 therapy in young breast cancer patients

Development and Validation of an Artificial Intelligence Digital Pathology Biomarker to Predict Benefit of Long-Term Hormonal Therapy and Radiotherapy in Men With High-Risk Prostate Cancer Across Multiple Phase III Trials

Are NCCN and EAU Active Surveillance Criteria Reliable in Patients With ISUP Grade-2 Intermediate-Risk Prostate Cancer? A Novel Model Integrating MRI to Predict Adverse Pathology

Developing an advanced risk stratification model for pediatric intracranial ependymoma based on the prospective trial E-HIT2000 and subsequent registries

Factors associated with longitudinal progression of the cumulative burden of morbidity and overall mortality after cisplatin-based chemotherapy for testicular cancer

LRP1B loss predicts sensitivity to immunotherapy in patients with NSCLC: an analysis of the phase 3 Checkmate 026 randomized trial

Olanzapine combined with standard antiemetics for the prevention of nausea and vomiting in patients with germ cell tumor undergoing a 5-day cisplatin-based chemotherapy (NAVIGATE study)： A phase III crossover trial

Does the benefit of neoadjuvant chemotherapy at six months predict long-term outcomes in colon or rectal cancer? A meta-analysis of randomised studies